SIONNA THERAPEUTICS INC (SION) Stock Overview
NASDAQ:SION - US8294011080 - Common Stock
SION Key Statistics, Chart & Performance
The current stock price of SION is 24 USD. In the past month the price increased by 38.89%.
SION Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 20.07 | 375.50B | ||
| AMGN | AMGEN INC | 13.01 | 152.70B | ||
| GILD | GILEAD SCIENCES INC | 14.86 | 142.76B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 23.38 | 101.56B | ||
| REGN | REGENERON PHARMACEUTICALS | 12.56 | 60.77B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 59.25B | ||
| ARGX | ARGENX SE - ADR | 80.99 | 45.95B | ||
| ONC | BEONE MEDICINES LTD-ADR | 6.89 | 40.63B | ||
| INSM | INSMED INC | N/A | 30.67B | ||
| BNTX | BIONTECH SE-ADR | N/A | 27.03B | ||
| NTRA | NATERA INC | N/A | 23.06B | ||
| BIIB | BIOGEN INC | 8.79 | 20.62B |
Related stock screener links
About SION
Company Profile
Sionna Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company. The company is headquartered in Waltham, Massachusetts and currently employs 41 full-time employees. The company went IPO on 2025-02-07. The firm is focused on researching and developing novel medicines for cystic fibrosis. The company is advancing a pipeline of small molecules engineered to correct the defects caused by the F508del genetic mutation, which resides in nucleotide-binding domain 1 (NBD1). The company is conducting ongoing Phase I trials of its two highly potent NBD1 stabilizers, SION-719 and SION-451, evaluating the safety, tolerability and pharmacokinetic (PK) profile of single and multiple ascending doses in healthy subjects. The company is also developing a portfolio of cystic fibrosis transmembrane conductance regulator (CFTR) modulators designed to work synergistically with its NBD1 stabilizers to improve CFTR function. Its portfolio also includes Galicaftor (SION-2222) and SION-2851, which are TMD1-directed CFTR correctors; SION-109, an ICL4-directed CFTR corrector, and Navocaftor (SION-3067), is a clinical-stage potentiator of CFTR gating activity.
Company Info
SIONNA THERAPEUTICS INC
21 Hickory Drive, Suite 500
Waltham MASSACHUSETTS US
Employees: 41
Phone: 16178192020
SIONNA THERAPEUTICS INC / SION FAQ
What is the stock price of SIONNA THERAPEUTICS INC today?
The current stock price of SION is 24 USD. The price increased by 4.08% in the last trading session.
What is the ticker symbol for SIONNA THERAPEUTICS INC stock?
The exchange symbol of SIONNA THERAPEUTICS INC is SION and it is listed on the Nasdaq exchange.
On which exchange is SION stock listed?
SION stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for SIONNA THERAPEUTICS INC stock?
9 analysts have analysed SION and the average price target is 39.27 USD. This implies a price increase of 63.63% is expected in the next year compared to the current price of 24. Check the SIONNA THERAPEUTICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is SIONNA THERAPEUTICS INC worth?
SIONNA THERAPEUTICS INC (SION) has a market capitalization of 1.06B USD. This makes SION a Small Cap stock.
How many employees does SIONNA THERAPEUTICS INC have?
SIONNA THERAPEUTICS INC (SION) currently has 41 employees.
What are the support and resistance levels for SIONNA THERAPEUTICS INC (SION) stock?
SIONNA THERAPEUTICS INC (SION) has a support level at 23.06. Check the full technical report for a detailed analysis of SION support and resistance levels.
Should I buy SIONNA THERAPEUTICS INC (SION) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of SION, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of SION, evaluating the profitability, health, valuation and growth aspects
- SIONNA THERAPEUTICS INC (SION) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- SIONNA THERAPEUTICS INC (SION) Sales and EPS estimates to see what analysts future expectations are.
- SIONNA THERAPEUTICS INC (SION) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- SIONNA THERAPEUTICS INC (SION) Insider and Institutional Ownership to learn about the owners and their transactions.
- SIONNA THERAPEUTICS INC (SION) Stock Chart to make your own analysis
- SIONNA THERAPEUTICS INC (SION) Latest news and press-releases to stay up to date.
Does SIONNA THERAPEUTICS INC (SION) stock pay dividends?
SION does not pay a dividend.
When does SIONNA THERAPEUTICS INC (SION) report earnings?
SIONNA THERAPEUTICS INC (SION) will report earnings on 2025-11-19.
What is the Price/Earnings (PE) ratio of SIONNA THERAPEUTICS INC (SION)?
SIONNA THERAPEUTICS INC (SION) does not have a PE ratio as the earnings reported over the last twelve months were negative (-2.23).
What is the Short Interest ratio of SIONNA THERAPEUTICS INC (SION) stock?
The outstanding short interest for SIONNA THERAPEUTICS INC (SION) is 12.26% of its float. Check the ownership tab for more information on the SION short interest.
SION Technical Analysis
ChartMill assigns a technical rating of 7 / 10 to SION.
SION Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to SION. SION has a great financial health rating, but its profitability evaluates not so good.
SION Financial Highlights
Over the last trailing twelve months SION reported a non-GAAP Earnings per Share(EPS) of -2.23. The EPS decreased by -30.53% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -27.34% | ||
| ROE | -28.61% | ||
| Debt/Equity | 0 |
SION Forecast & Estimates
9 analysts have analysed SION and the average price target is 39.27 USD. This implies a price increase of 63.63% is expected in the next year compared to the current price of 24.